Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Oncology reports

Volumn 6, Issue 5, 1999, Pages 1097-1099

  Ellerhorst, J A ^a   Bedikian, A ^a   Ring, S ^a   Buzaid, A C ^a   Eton, O ^a   Legha, S S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN;

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 0033192736     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.5.1097     Document Type: Article

References (0)